High Copy Number Expression Vectors for lacZ β-Galactosidase.

Marker Gene provides a variety of high copy number expression vectors for lacZ β-Galactosidase and is constantly developing new vectors and systems. Feel free to call our technical assistance staff for more information about these or other molecular biology products for your research.

Product ID Product Name Description
M0951 pCMVß Mammalian lacZ Expression Vector  This high copy number eukaryotic vector, pCMVβ expresses the full-length β-galactosidase gene under the control of the cytomegalovirus immediate early gene (CMV IE) promoter. This vector is very useful for transfection of mammalian cells in culture and for use in other species. The b-galactosidase enzyme expression is enhanced by elements including: SD/SA-RNA splice donor and acceptor sequence, and SV40 late polyadenylylation signal. pCMVβ expression vector also contains β-lactamase gene, which acts as a selection marker (100ug/mL ampicillin resistance) in E. coli host. pCMVβ vector has been tested to generate up to 2530u/mg cell extract (MacGregor, and Caskey). In addition, the β-galactosidase gene can be excised using the NotI sites to allow the insertion of other genes to be expressed under the same regulatory elements in mammalian cells. See also our pSV40β vector system, Product M0952. 
M0952 pSV40ß Mammalian lacZ Expression Vector  This common eukaryotic expression vector, pSV40β expresses the full-length β-galactosidase gene under the control of simian virus 40 (SV40) early promoter. This vector is very useful for transfection of mammalian cells in culture and for use in other species. The β-galactosidase enzyme expression is enhanced by elements including: SD/SA-RNA splice donor and acceptor sequence, and SV40 late polyadenylylation signal. pSV40β expression vector also contains β-lactamase, which acts as a selection marker (100 ug/ml ampicillin resistance) in E. coli host. See also our pCMVβ vector system, Product M0951. 
M1015 pCMVß Mammalian lacZco Expression Vector  This high copy number eukaryotic vector, pCMVβ expresses the full-length codon-optimized β-galactosidase gene (lacZco) under the control of the cytomegalovirus immediate early gene (CMV IE) promoter. When expressed in mammalian cells, the codon-optimized gene results in expression levels of β-galactosidase 15-fold higher than those resulting from an analogous construct containing the native E. coli gene sequence. Enhanced transcript stability and increased translational efficiency provide for increased β-galactosidase expression, as suggested by RNA analysis. In addition, codon-optimization results in the elimination of several cryptic splice acceptor sites that are present in the native E. coli gene sequence and increases the amounts of un-spliced, full-length genomic RNA when used in a lentiviral vector containing a 5' splice donor.1 The β-galactosidase enzyme expression is also enhanced by the SV40 late polyadenylylation signal. This pCMVβ expression vector contains the β-lactamase gene, which acts as a selection marker (100ug/mL ampicillin resistance) in E. coli host. pCMVβ vector has been tested to generate up to 2530u/mg cell extract (MacGregor, and Caskey). If desired, the β-galactosidase codon optimized gene can be excised using XhoI and NotI sites to allow the insertion of other genes to be expressed under the same regulatory elements in mammalian cells. See also our pSV40β lacZco vector system, Product M1016. 
M1016 pSV40ß Mammalian lacZco Expression Vector  This common eukaryotic expression vector, pSV40β expresses the full-length codon-optimized β-galactosidase gene (lacZco) under the control of simian virus 40 (SV40) early promoter. When expressed in mammalian cells, the codon-optimized gene results in expression levels of β-galactosidase 15-fold higher than those resulting from an analogous construct containing the native E. coli gene sequence. Enhanced transcript stability and increased translational efficiency provide for increased β-galactosidase expression, as suggested by RNA analysis. In addition, codon-optimization results in the elimination of several cryptic splice acceptor sites that are present in the native E. coli gene sequence and increases the amounts of un-spliced, full-length genomic RNA when used in a lentiviral vector containing a 5' splice donor.1 The β-galactosidase enzyme expression is also enhanced by the SV40 late polyadenylylation signal. The pSV40β expression vector also contains β-lactamase, which acts as a selection marker (100 ug/ml ampicillin resistance) in E. coli host. If desired, the β-galactosidase codon optimized gene can be excised using XhoI and NotI sites to allow the insertion of other genes to be expressed under the same regulatory elements in mammalian cells. See also our pCMVβ lacZco vector system, Product M1015. 
M1017 pCMVß Mammalian lacZnls12co Expression Vector  This high copy number eukaryotic vector, pCMVβ expresses the full-length codon-optimized β-galactosidase gene (lacZco) with an effective nuclear localization signal under the control of the cytomegalovirus immediate early gene (CMV IE) promoter. When expressed in mammalian cells, the codon-optimized gene results in expression levels of β-galactosidase 15-fold higher than those resulting from an analogous construct containing the native E. coli gene sequence. Enhanced transcript stability and increased translational efficiency provide for increased β-galactosidase expression, as suggested by RNA analysis. In addition, codon-optimization results in the elimination of several cryptic splice acceptor sites that are present in the native E. coli gene sequence and increases the amounts of un-spliced, full-length genomic RNA when used in a lentiviral vector containing a 5' splice donor. The nls12 variant results from the addition of a twelve amino acid sequence, ProLysLysLysArgLysValGluAspProLysAsp (from the SV40 T antigen nuclear localization signal) after the methionine initiation residue 1. The β-galactosidase enzyme expression is also enhanced by the SV40 late polyadenylylation signal. This pCMVβ expression vector contains the β-lactamase gene, which acts as a selection marker (100ug/mL ampicillin resistance) in E. coli host. pCMVβ vector has been tested to generate up to 2530u/mg cell extract (MacGregor, and Caskey). If desired, the b-galactosidase codon optimized gene can be excised using XhoI and NotI sites to allow the insertion of other genes to be expressed under the same regulatory elements in mammalian cells. See also our pSV40b lacZnls12co vector system, Product M1080. 
M1018 pSV40ß Mammalian lacZnls12co Expression Vector  The eukaryotic expression vector, pSV40β expresses the full-length codon-optimized β-galactosidase gene (lacZco) under the control of simian virus 40 (SV40) early promoter. When expressed in mammalian cells, the codon-optimized gene results in expression levels of β-galactosidase 15-fold higher than those resulting from an analogous construct containing the native E. coli gene sequence. Enhanced transcript stability and increased translational efficiency provide for increased β-galactosidase expression, as suggested by RNA analysis. In addition, codon-optimization results in the elimination of several cryptic splice acceptor sites that are present in the native E. coli gene sequence and increases the amounts of un-spliced, full-length genomic RNA when used in a lentiviral vector containing a 5'-splice donor. The nls12 variant results from the addition of a twelve amino acid sequence, ProLysLysLysArgLysValGluAspProLysAsp (from the SV40 T antigen nuclear localization signal) after the methionine initiation residue.1 The β-galactosidase enzyme expression is also enhanced by the SV40 late polyadenylylation signal. The pSV40b expression vector also contains β-lactamase, which acts as a selection marker (100 ug/ml ampicillin resistance) in E. coli host. If desired, the β-galactosidase codon optimized gene can be excised using XhoI and NotI sites to allow the insertion of other genes to be expressed under the same regulatory elements in mammalian cells. See also our pCMVb lacZco vector system, Product M1017. 
     
  ©2008 Marker Gene Technologies, Inc.